Drug therapy underpins nearly every aspect of cardiovascular care, and Cardiac Pharmacology provides the framework for using medications safely and effectively across diverse conditions. This session reviews foundational principles of pharmacokinetics and pharmacodynamics, then applies them to real-world management of hypertension, heart failure, ischemic heart disease, arrhythmias, and thrombosis. Participants will learn how to select, titrate, and combine therapies to maximize benefit while minimizing adverse effects, interactions, and polypharmacy burden.

As new agents and combinations emerge, many clinicians seek a cardiology conference to align practice with current evidence and guidelines. This session examines major drug classes—beta-blockers, ACE inhibitors, ARNI, SGLT2 inhibitors, mineralocorticoid antagonists, calcium-channel blockers, antianginal agents, antiarrhythmics, antithrombotics, and lipid-lowering therapies. Attendees will review key trial data and practical pearls for dosing in renal or hepatic dysfunction, elderly populations, and patients with multiple comorbidities. Special attention is given to stepwise heart failure regimens, combination antihypertensive strategies, and rational use of dual or triple antithrombotic therapy.

A central theme is implementing evidence-based cardiovascular pharmacotherapy in busy clinics and hospitals. Participants will learn how to use protocols, order sets, and pharmacist-led initiatives to accelerate optimization of guideline-directed medical therapy. The session covers common pitfalls, such as under-dosing life-saving medications, overlooking contraindications, or failing to de-escalate when bleeding or hypotension emerges. Case-based discussions illustrate how careful medication review can resolve dizziness, fatigue, or orthostatic symptoms without sacrificing cardiovascular protection.

The session concludes by exploring future directions, including novel lipid agents, anti-inflammatory drugs, gene-targeted therapies, and personalized dosing based on pharmacogenomics. Attendees will consider how to evaluate new drugs critically, balance cost against benefit, and discuss complex regimens with patients in understandable terms. By the end, participants will be better equipped to construct and maintain rational, individualized pharmacologic plans for their cardiac patients.